{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# GNBR Knowledge Graph Endpoint"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This endpoint takes in a knowledge graph from another reasoner, and returns a network supporting setnences from GNBR."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import requests\n",
    "\n",
    "def post(question):\n",
    "    url=f'https://gnbr-reason.ncats.io/gnbr'\n",
    "    print(url)\n",
    "    response = requests.post(url,json=question)\n",
    "    print( f\"Return Status: {response.status_code}\" )\n",
    "    if response.status_code == 200:\n",
    "        return response.json()\n",
    "    return {}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Load WF1 module 1 output from rtx"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('wf1mod1_1_ebola_gamma.txt') as f:\n",
    "    rtx = json.load(f)\n",
    "\n",
    "for edge in rtx['result_list'][0]['result_graph']['edge_list']:\n",
    "    edge['publications'] = list(edge['publications'].split(','))\n",
    "\n",
    "node_list = rtx['result_list'][0]['result_graph']['node_list']\n",
    "edge_list = rtx['result_list'][0]['result_graph']['edge_list']\n",
    "\n",
    "query_graph = {\n",
    "    'nodes': node_list, \n",
    "    'edges': edge_list\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Construct query object"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [],
   "source": [
    "query = {\n",
    "    \"query_message\": {\n",
    "        \"query_graph\": query_graph\n",
    "    }\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Post Query to Endpoint"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://gnbr-reason.ncats.io/gnbr\n",
      "Return Status: 200\n"
     ]
    }
   ],
   "source": [
    "result_graph = post(query)['results'][0]['result_graph']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Print results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'edges': [{'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14639531',\n",
      "                                 'value': 'Mechanisms underlying '\n",
      "                                          'coagulation_abnormalities in '\n",
      "                                          'ebola_hemorrhagic_fever : '\n",
      "                                          'overexpression of tissue_factor in '\n",
      "                                          'primate monocytes/macrophages is a '\n",
      "                                          'key event .'}],\n",
      "            'publications': ['PUBMED:14639531'],\n",
      "            'source_id': 'MESH:D018376',\n",
      "            'target_id': 'NCBIGENE:2152'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19805682',\n",
      "                                 'value': 'This cohort study aimed to '\n",
      "                                          'calculate the incidence of and '\n",
      "                                          'identify the risk factors for ONJ '\n",
      "                                          'in patients with cancer treated '\n",
      "                                          'with intravenous zoledronate , '\n",
      "                                          'ibandronate , and pamidronate .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'}],\n",
      "            'publications': ['PUBMED:19805682', 'PUBMED:21343556'],\n",
      "            'source_id': 'MESH:C088658',\n",
      "            'target_id': 'MESH:D009369'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:C088658',\n",
      "            'target_id': 'MESH:D001943'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'PURPOSE : This study compared '\n",
      "                                          'denosumab , a fully human '\n",
      "                                          'monoclonal anti-receptor activator '\n",
      "                                          'of nuclear factor kappa-B ligand '\n",
      "                                          'antibody , with zoledronic_acid '\n",
      "                                          '-LRB- ZA -RRB- for delaying or '\n",
      "                                          'preventing skeletal-related events '\n",
      "                                          '-LRB- SRE -RRB- in patients with '\n",
      "                                          'advanced_cancer and bone metastases '\n",
      "                                          '-LRB- excluding breast and prostate '\n",
      "                                          '-RRB- or myeloma .'}],\n",
      "            'publications': ['PUBMED:21343556', 'PUBMED:21343556'],\n",
      "            'source_id': 'MESH:C088658',\n",
      "            'target_id': 'MESH:D009362'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The potential role of thalidomide '\n",
      "                                          'in the treatment of human neoplasia '\n",
      "                                          'will be confirmed by means of '\n",
      "                                          'randomized clinical trials .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The breakthrough discovery of the '\n",
      "                                          'anti-angiogenic effects of '\n",
      "                                          'thalidomide gave impetus to a '\n",
      "                                          'series of clinical trials in '\n",
      "                                          'patients with solid tumors and '\n",
      "                                          'hematologic_malignancies .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/23297129',\n",
      "                                 'value': 'A randomized phase 3 trial of '\n",
      "                                          'thalidomide and prednisone as '\n",
      "                                          'maintenance therapy after ASCT in '\n",
      "                                          'patients with MM with a '\n",
      "                                          'quality-of-life assessment : the '\n",
      "                                          'National Cancer Institute of Canada '\n",
      "                                          'Clinicals Trials Group Myeloma 10 '\n",
      "                                          'Trial .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Thalidomide is an antiangiogenic '\n",
      "                                          'drug used in cancer therapy .'}],\n",
      "            'publications': ['PUBMED:11188934',\n",
      "                             'PUBMED:11188934',\n",
      "                             'PUBMED:23297129',\n",
      "                             'PUBMED:17514361'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D013792'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'}],\n",
      "            'publications': ['PUBMED:22196580'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:C571496'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'}],\n",
      "            'publications': ['PUBMED:20022634'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:5290'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Tumor cells were treated with '\n",
      "                                          '5-azacytidine and a panel of '\n",
      "                                          'cytokines were used to determine '\n",
      "                                          'their ability to induce SPAN-Xb '\n",
      "                                          'expression .'}],\n",
      "            'publications': ['PUBMED:16187275'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D001374'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'SPAN-Xb is a novel cancer-testis '\n",
      "                                          'antigen in multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:16187275', 'PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D009101'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'SPAN-Xb is a novel cancer-testis '\n",
      "                                          'antigen in multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:16187275'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:728695'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'Extensive evidence has shown that '\n",
      "                                          'epoetin is effective in the '\n",
      "                                          'treatment of '\n",
      "                                          'cancer-associated_anemia .'}],\n",
      "            'publications': ['PUBMED:12111647'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:2056'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2803933',\n",
      "                                 'value': 'We conclude that IL2 may be used in '\n",
      "                                          'minimal residual '\n",
      "                                          'haematological_malignancy , and by '\n",
      "                                          'producing anti-neoplastic effector '\n",
      "                                          'cells has the potential , as yet '\n",
      "                                          'unproven , to prolong disease-free '\n",
      "                                          'survival of patients entering '\n",
      "                                          'remission .'}],\n",
      "            'publications': ['PUBMED:2803933'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:3558'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D001943'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D009362'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Acute-phase reactions after the '\n",
      "                                          'first dose occurred more frequently '\n",
      "                                          'with ZA , as did renal adverse '\n",
      "                                          'events and elevations in serum '\n",
      "                                          'creatinine based on National Cancer '\n",
      "                                          'Institute Common Toxicity Criteria '\n",
      "                                          'for Adverse Events grading .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D064420'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Acute-phase reactions after the '\n",
      "                                          'first dose occurred more frequently '\n",
      "                                          'with ZA , as did renal adverse '\n",
      "                                          'events and elevations in serum '\n",
      "                                          'creatinine based on National Cancer '\n",
      "                                          'Institute Common Toxicity Criteria '\n",
      "                                          'for Adverse Events grading .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D003404'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D007938'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'MESH:D001554'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:7157'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:644914'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:4193'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'MESH:D009369',\n",
      "            'target_id': 'NCBIGENE:1869'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7387286',\n",
      "                                 'value': 'The infection responded to '\n",
      "                                          'treatment with antibiotics , '\n",
      "                                          'including penicillin_G , to which '\n",
      "                                          'the organism was sensitive .'}],\n",
      "            'publications': ['PUBMED:7387286'],\n",
      "            'source_id': 'MESH:D007239',\n",
      "            'target_id': 'MESH:D010400'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'These results indicate that AZT is '\n",
      "                                          'an effective and safe antibiotic '\n",
      "                                          'for the treatment of infections '\n",
      "                                          'accompanying hematologic_disorders '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:4079014', 'PUBMED:4079014'],\n",
      "            'source_id': 'MESH:D007239',\n",
      "            'target_id': 'MESH:D006402'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'}],\n",
      "            'publications': ['PUBMED:4079014'],\n",
      "            'source_id': 'MESH:D007239',\n",
      "            'target_id': 'MESH:D001398'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'These results indicate that AZT is '\n",
      "                                          'an effective and safe antibiotic '\n",
      "                                          'for the treatment of infections '\n",
      "                                          'accompanying hematologic_disorders '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:4079014', 'PUBMED:4079014'],\n",
      "            'source_id': 'MESH:D007239',\n",
      "            'target_id': 'MESH:D015215'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'}],\n",
      "            'publications': ['PUBMED:3859250'],\n",
      "            'source_id': 'MESH:C020766',\n",
      "            'target_id': 'MESH:D019337'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'In the present study , we have used '\n",
      "                                          'a pair of sequence-specific primers '\n",
      "                                          'in reverse transcription-polymerase '\n",
      "                                          'chain reaction -LRB- RT-PCR -RRB- '\n",
      "                                          'and sequence analysis to '\n",
      "                                          'demonstrate that the X-linked gene '\n",
      "                                          'encoding SPAN-Xb is expressed in '\n",
      "                                          'multiple_myeloma and other '\n",
      "                                          'hematologic_malignancies such as '\n",
      "                                          'chronic_lymphocytic_leukemia -LRB- '\n",
      "                                          'CLL -RRB- , '\n",
      "                                          'chronic_myeloid_leukemia -LRB- CML '\n",
      "                                          '-RRB- , and acute_myeloid_leukemia '\n",
      "                                          '-LRB- AML -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Gene expression and immunologic '\n",
      "                                          'consequence of SPAN-Xb in myeloma '\n",
      "                                          'and other hematologic_malignancies '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:12393489', 'PUBMED:12393489'],\n",
      "            'source_id': 'MESH:D019337',\n",
      "            'target_id': 'NCBIGENE:728695'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Gene expression and immunologic '\n",
      "                                          'consequence of SPAN-Xb in myeloma '\n",
      "                                          'and other hematologic_malignancies '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:12393489'],\n",
      "            'source_id': 'MESH:D019337',\n",
      "            'target_id': 'MESH:D009101'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19399582',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19399582',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19399582',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'}],\n",
      "            'publications': ['PUBMED:16596146',\n",
      "                             'PUBMED:11521808',\n",
      "                             'PUBMED:11521808',\n",
      "                             'PUBMED:11521808',\n",
      "                             'PUBMED:19399582',\n",
      "                             'PUBMED:19399582',\n",
      "                             'PUBMED:19399582',\n",
      "                             'PUBMED:21501555',\n",
      "                             'PUBMED:21501555',\n",
      "                             'PUBMED:18624684',\n",
      "                             'PUBMED:15148528',\n",
      "                             'PUBMED:17514361',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:18565291'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D013792'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'}],\n",
      "            'publications': ['PUBMED:7243808'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'CHEBI:35341'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'}],\n",
      "            'publications': ['PUBMED:7243808'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D058186'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'}],\n",
      "            'publications': ['PUBMED:11521808', 'PUBMED:11521808'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D003907'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17026821',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17026821',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17026821',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'}],\n",
      "            'publications': ['PUBMED:21501555',\n",
      "                             'PUBMED:21501555',\n",
      "                             'PUBMED:17026821',\n",
      "                             'PUBMED:17026821',\n",
      "                             'PUBMED:17026821',\n",
      "                             'PUBMED:22196580',\n",
      "                             'PUBMED:16772605',\n",
      "                             'PUBMED:16772605',\n",
      "                             'PUBMED:16772605'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:C400082'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:22196580',\n",
      "                             'PUBMED:22196580',\n",
      "                             'PUBMED:22196580'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:C571496'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Gene expression and immunologic '\n",
      "                                          'consequence of SPAN-Xb in myeloma '\n",
      "                                          'and other hematologic_malignancies '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Our results provide the first '\n",
      "                                          'evidence showing the role of '\n",
      "                                          'promoter methylation in the primary '\n",
      "                                          'regulation of SPAN-Xb and the '\n",
      "                                          'ability of IL-7 and GM-CSF to '\n",
      "                                          'further enhance SPAN-Xb gene and '\n",
      "                                          'protein expression in myeloma cells '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'SPAN-Xb expression in myeloma cells '\n",
      "                                          'is dependent on promoter '\n",
      "                                          'hypomethylation and can be '\n",
      "                                          'upregulated pharmacologically .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'SPAN-Xb is a novel cancer-testis '\n",
      "                                          'antigen in multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'In this study , we determined the '\n",
      "                                          'mechanisms regulating SPAN-Xb '\n",
      "                                          'expression in MM .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Both IL-7 and GM-CSF were also able '\n",
      "                                          'to upregulate the expression of '\n",
      "                                          'SPAN-Xb in myeloma cells , but only '\n",
      "                                          'after the promoter sequence has '\n",
      "                                          'been hypomethylated .'}],\n",
      "            'publications': ['PUBMED:12393489',\n",
      "                             'PUBMED:16187275',\n",
      "                             'PUBMED:16187275',\n",
      "                             'PUBMED:16187275',\n",
      "                             'PUBMED:16187275',\n",
      "                             'PUBMED:16187275'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:728695'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Both IL-7 and GM-CSF were also able '\n",
      "                                          'to upregulate the expression of '\n",
      "                                          'SPAN-Xb in myeloma cells , but only '\n",
      "                                          'after the promoter sequence has '\n",
      "                                          'been hypomethylated .'}],\n",
      "            'publications': ['PUBMED:16187275'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:3574'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'The type I melanoma antigen gene '\n",
      "                                          '-LRB- MAGE -RRB- proteins CT7 -LRB- '\n",
      "                                          'MAGE-C1 -RRB- and MAGE-A3 are '\n",
      "                                          'commonly expressed in '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- , '\n",
      "                                          'and their expression correlates '\n",
      "                                          'with increased plasma cell '\n",
      "                                          'proliferation and poor clinical '\n",
      "                                          'outcome .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'Cellular immune responses against '\n",
      "                                          'CT7 -LRB- MAGE-C1 -RRB- and humoral '\n",
      "                                          'responses against other '\n",
      "                                          'cancer-testis antigens in '\n",
      "                                          'multiple_myeloma patients .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'CT7 and MAGE-A3 are promising '\n",
      "                                          'antigenic targets for therapeutic '\n",
      "                                          'tumor vaccines in myeloma ; '\n",
      "                                          'therefore , it is critical to '\n",
      "                                          'determine if they are immunogenic '\n",
      "                                          'in MM patients .'}],\n",
      "            'publications': ['PUBMED:20108890',\n",
      "                             'PUBMED:20108890',\n",
      "                             'PUBMED:20108890'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:9947'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'An international expert panel met '\n",
      "                                          'to develop treatment '\n",
      "                                          'recommendations for the use of '\n",
      "                                          'epoetin in MM and CLL patients .'}],\n",
      "            'publications': ['PUBMED:12111647'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:2056'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179397',\n",
      "                                 'value': 'PURPOSE : To prospectively assess '\n",
      "                                          'molecular imaging of '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- by '\n",
      "                                          'using the '\n",
      "                                          'radiolabeled_amino_acid_carbon_11 '\n",
      "                                          '-LRB- -LRB- 11 -RRB- C -RRB- '\n",
      "                                          'methionine and positron emission '\n",
      "                                          'tomography -LRB- PET -RRB- / '\n",
      "                                          'computed tomography -LRB- CT -RRB- '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:17179397'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D008715'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D007938'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D001554'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'In this study , we examined MDM2 '\n",
      "                                          'expression and function in '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- '\n",
      "                                          'cells .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:4193'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'The novel , proteasome-independent '\n",
      "                                          'NF-kappaB inhibitor V1810 induces '\n",
      "                                          'apoptosis and cell cycle arrest in '\n",
      "                                          'multiple_myeloma and overcomes '\n",
      "                                          'NF-kappaB-mediated drug resistance '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Taken together , the novel , '\n",
      "                                          'proteasome-independent NF-kappaB '\n",
      "                                          'inhibitor V1810 induces apoptosis '\n",
      "                                          'and cell cycle arrest in '\n",
      "                                          'multiple_myeloma cells at a '\n",
      "                                          'concentration range that can be '\n",
      "                                          'achieved in vivo .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'At this concentration , V1810 '\n",
      "                                          'potently induces apoptosis in all '\n",
      "                                          'four multiple_myeloma cell lines '\n",
      "                                          'assessed -LRB- IC -LRB- 50 -RRB- = '\n",
      "                                          '5-12 micromol/L -RRB- as well as in '\n",
      "                                          'primary multiple_myeloma cells '\n",
      "                                          '-LRB- IC -LRB- 50 -RRB- = 5-40 '\n",
      "                                          'micromol/L -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'V1810 and melphalan synergistically '\n",
      "                                          'decrease multiple_myeloma cell '\n",
      "                                          'viability .'}],\n",
      "            'publications': ['PUBMED:20124446',\n",
      "                             'PUBMED:20124446',\n",
      "                             'PUBMED:20124446',\n",
      "                             'PUBMED:20124446'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:C553325'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'The novel , proteasome-independent '\n",
      "                                          'NF-kappaB inhibitor V1810 induces '\n",
      "                                          'apoptosis and cell cycle arrest in '\n",
      "                                          'multiple_myeloma and overcomes '\n",
      "                                          'NF-kappaB-mediated drug resistance '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Taken together , the novel , '\n",
      "                                          'proteasome-independent NF-kappaB '\n",
      "                                          'inhibitor V1810 induces apoptosis '\n",
      "                                          'and cell cycle arrest in '\n",
      "                                          'multiple_myeloma cells at a '\n",
      "                                          'concentration range that can be '\n",
      "                                          'achieved in vivo .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Evidence is increasing that '\n",
      "                                          'aberrant NF-kappaB activation is '\n",
      "                                          'crucial for multiple_myeloma '\n",
      "                                          'pathophysiology and a promising '\n",
      "                                          'target for new antimyeloma '\n",
      "                                          'therapies .'}],\n",
      "            'publications': ['PUBMED:20124446',\n",
      "                             'PUBMED:20124446',\n",
      "                             'PUBMED:20124446'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:4790'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Therefore , BMP-2 induces apoptosis '\n",
      "                                          'in various human myeloma cells by '\n",
      "                                          'means of the down-regulation of '\n",
      "                                          'Bcl-x -LRB- L -RRB- and by '\n",
      "                                          'cell-cycle arrest through the '\n",
      "                                          'up-regulation of p21 -LRB- '\n",
      "                                          'CIP1/WAF1 -RRB- and p27 -LRB- KIP1 '\n",
      "                                          '-RRB- and by the '\n",
      "                                          'hypophosphorylation of Rb .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Bone_morphogenetic_protein-2 '\n",
      "                                          'induces apoptosis in human myeloma '\n",
      "                                          'cells with modulation of STAT3 .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'We show in this report a novel '\n",
      "                                          'function of BMPs in hematopoietic '\n",
      "                                          'cells : BMP-2 induces apoptosis not '\n",
      "                                          'only in human myeloma cell lines '\n",
      "                                          '-LRB- U266 , RPMI 8226 , HS-Sultan '\n",
      "                                          ', IM-9 , OPM-2 , and KMS-12 cells '\n",
      "                                          '-RRB- , but also in primary samples '\n",
      "                                          'from patients with multiple_myeloma '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'We conclude that BMP-2 would be '\n",
      "                                          'useful as a novel therapeutic agent '\n",
      "                                          'in the treatment of '\n",
      "                                          'multiple_myeloma both by means of '\n",
      "                                          'its antitumor effect of inducing '\n",
      "                                          'apoptotis and through its original '\n",
      "                                          'bone-inducing activity , because '\n",
      "                                          'bone_lesions are frequently seen in '\n",
      "                                          'myeloma patients .'}],\n",
      "            'publications': ['PUBMED:10979940',\n",
      "                             'PUBMED:10979940',\n",
      "                             'PUBMED:10979940',\n",
      "                             'PUBMED:10979940'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:650'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Bone_morphogenetic_protein-2 '\n",
      "                                          'induces apoptosis in human myeloma '\n",
      "                                          'cells with modulation of STAT3 .'}],\n",
      "            'publications': ['PUBMED:10979940'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:6774'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'}],\n",
      "            'publications': ['PUBMED:17514361', 'PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D013927'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'A Korean trial reported low TE '\n",
      "                                          'incidence in thalidomide-treated '\n",
      "                                          'myeloma patients -LRB- 39 % were '\n",
      "                                          'given aspirin prophylactically '\n",
      "                                          '-RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'}],\n",
      "            'publications': ['PUBMED:22706703',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D013923'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'A Korean trial reported low TE '\n",
      "                                          'incidence in thalidomide-treated '\n",
      "                                          'myeloma patients -LRB- 39 % were '\n",
      "                                          'given aspirin prophylactically '\n",
      "                                          '-RRB- .'}],\n",
      "            'publications': ['PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D001241'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'}],\n",
      "            'publications': ['PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D054556'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440338',\n",
      "                                 'value': 'We studied IL-3 in 7 patients with '\n",
      "                                          'markedly delayed engraftment after '\n",
      "                                          'autologous bone marrow '\n",
      "                                          'transplantation -LRB- ABMT -RRB- '\n",
      "                                          'for hematologic_malignancies -LRB- '\n",
      "                                          'acute_myeloid_leukemia 4 , '\n",
      "                                          'chronic_myeloid_leukemia 1 , '\n",
      "                                          \"myeloma 1 , non-Hodgkin 's _ \"\n",
      "                                          'lymphoma 1 -RRB- .'}],\n",
      "            'publications': ['PUBMED:8440338'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D015464'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440338',\n",
      "                                 'value': 'We studied IL-3 in 7 patients with '\n",
      "                                          'markedly delayed engraftment after '\n",
      "                                          'autologous bone marrow '\n",
      "                                          'transplantation -LRB- ABMT -RRB- '\n",
      "                                          'for hematologic_malignancies -LRB- '\n",
      "                                          'acute_myeloid_leukemia 4 , '\n",
      "                                          'chronic_myeloid_leukemia 1 , '\n",
      "                                          \"myeloma 1 , non-Hodgkin 's _ \"\n",
      "                                          'lymphoma 1 -RRB- .'}],\n",
      "            'publications': ['PUBMED:8440338'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:3562'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7605999',\n",
      "                                 'value': 'In patients with advanced '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- '\n",
      "                                          'there is an excess of production of '\n",
      "                                          'interleukin-6 -LRB- IL-6 -RRB- in '\n",
      "                                          'vivo , and elevated serum levels '\n",
      "                                          'are associated with plasmablastic '\n",
      "                                          'proliferative activity and short '\n",
      "                                          'survival .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7605999',\n",
      "                                 'value': 'These data show that anti-IL-6 MoAb '\n",
      "                                          'can suppress the proliferation of '\n",
      "                                          'myeloma cells and underscore the '\n",
      "                                          'biologic role of IL-6 for myeloma '\n",
      "                                          'growth in vivo .'}],\n",
      "            'publications': ['PUBMED:7605999', 'PUBMED:7605999'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'NCBIGENE:3569'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'}],\n",
      "            'publications': ['PUBMED:18565291'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:C467567'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11563589',\n",
      "                                 'value': 'The survival time of myeloma '\n",
      "                                          'patients improved from a few months '\n",
      "                                          'to many years after treatment with '\n",
      "                                          'melphalan .'}],\n",
      "            'publications': ['PUBMED:11563589'],\n",
      "            'source_id': 'MESH:D009101',\n",
      "            'target_id': 'MESH:D008558'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'The advent of efficacious low '\n",
      "                                          'toxicity chemotherapy -LRB- such as '\n",
      "                                          'thalidomide and bortezomib -RRB- '\n",
      "                                          'and new dialysis techniques to '\n",
      "                                          'remove free light chains may '\n",
      "                                          'radically alter the outcome of this '\n",
      "                                          'group of patients .'}],\n",
      "            'publications': ['PUBMED:19767634'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D064420'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'}],\n",
      "            'publications': ['PUBMED:11521808',\n",
      "                             'PUBMED:11521808',\n",
      "                             'PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D003907'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has shown clinical '\n",
      "                                          'antitumor activity in single-agent '\n",
      "                                          ', phase II clinical trials in '\n",
      "                                          'AIDS-related Kaposi_sarcoma , '\n",
      "                                          'glioma , multiple_myeloma '\n",
      "                                          'refractory to chemotherapy , and '\n",
      "                                          'hormone-refractory_prostate_cancer '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:11188934'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D012514'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has been shown to block '\n",
      "                                          'the activity of angiogenic '\n",
      "                                          'substances like bFGF , VEGF and '\n",
      "                                          'interleukin_6 .'}],\n",
      "            'publications': ['PUBMED:11188934'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'NCBIGENE:2247'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'}],\n",
      "            'publications': ['PUBMED:21501555', 'PUBMED:21501555'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:C400082'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'}],\n",
      "            'publications': ['PUBMED:15148528'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D002292'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'publications': ['PUBMED:15148528'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D004893'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'In the thrombosis cohort , four '\n",
      "                                          'patients -LRB- 80 % -RRB- were '\n",
      "                                          'treated with thalidomide plus '\n",
      "                                          'dexamethasone .'}],\n",
      "            'publications': ['PUBMED:17514361',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D013927'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'In conclusion , this side effect of '\n",
      "                                          'the use of thalidomide should be '\n",
      "                                          'taken into consideration while '\n",
      "                                          'doing examinations with respect to '\n",
      "                                          'the etiology in arterial '\n",
      "                                          'thromboembolism and because of this '\n",
      "                                          'vascular complication that '\n",
      "                                          'threatens life ; we suggest '\n",
      "                                          'stopping the thalidomide treatment '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'}],\n",
      "            'publications': ['PUBMED:17514361',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703',\n",
      "                             'PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D013923'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Of the patients in the '\n",
      "                                          'relapsed/refractory cohort -LRB- n '\n",
      "                                          '= 114 -RRB- who were given '\n",
      "                                          'thalidomide alone , none -LRB- 0/52 '\n",
      "                                          '-RRB- developed venous_TE -LRB- VTE '\n",
      "                                          '-RRB- ; however , two patients '\n",
      "                                          '-LRB- 2/35 , 5.7 % -RRB- who were '\n",
      "                                          'given thalidomide-dexamethasone as '\n",
      "                                          'a salvage treatment developed VTE '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:22706703', 'PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:D054556'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'}],\n",
      "            'publications': ['PUBMED:18565291'],\n",
      "            'source_id': 'MESH:D013792',\n",
      "            'target_id': 'MESH:C467567'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'}],\n",
      "            'publications': ['PUBMED:10074605'],\n",
      "            'source_id': 'MESH:D007674',\n",
      "            'target_id': 'MESH:D058186'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'}],\n",
      "            'publications': ['PUBMED:10074605'],\n",
      "            'source_id': 'MESH:D007674',\n",
      "            'target_id': 'NCBIGENE:1636'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'Acute_renal_failure from '\n",
      "                                          'multiple_myeloma precipitated by '\n",
      "                                          'ACE inhibitors .'}],\n",
      "            'publications': ['PUBMED:10074605', 'PUBMED:10074605'],\n",
      "            'source_id': 'MESH:D058186',\n",
      "            'target_id': 'NCBIGENE:1636'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Four patients with '\n",
      "                                          'acute_renal_failure due to myeloma '\n",
      "                                          '-LRB- IgG with lambda , lambda , '\n",
      "                                          'lambda , IgG with kappa -RRB- were '\n",
      "                                          'studied ; serum creatinine was 4.7 '\n",
      "                                          ', 5.9 , 4.25 , 10.8 mg % , and '\n",
      "                                          'proteinuria 2.1 , 2.8 , 5.2 , 4.2 '\n",
      "                                          'g/24h respectively .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'BACKGROUND : Myeloma is the second '\n",
      "                                          'most common haematological '\n",
      "                                          'malignancy and is a cause of severe '\n",
      "                                          'acute_kidney_injury -LRB- serum '\n",
      "                                          'creatinine > or = 500 micromol/L '\n",
      "                                          '-RRB- that has long been associated '\n",
      "                                          'with a poor prognosis , although '\n",
      "                                          'previous series have been small .'}],\n",
      "            'publications': ['PUBMED:7243808', 'PUBMED:19767634'],\n",
      "            'source_id': 'MESH:D058186',\n",
      "            'target_id': 'MESH:D003404'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'}],\n",
      "            'publications': ['PUBMED:7243808'],\n",
      "            'source_id': 'MESH:D058186',\n",
      "            'target_id': 'CHEBI:35341'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Acute-phase reactions after the '\n",
      "                                          'first dose occurred more frequently '\n",
      "                                          'with ZA , as did renal adverse '\n",
      "                                          'events and elevations in serum '\n",
      "                                          'creatinine based on National Cancer '\n",
      "                                          'Institute Common Toxicity Criteria '\n",
      "                                          'for Adverse Events grading .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:D003404',\n",
      "            'target_id': 'MESH:D064420'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'publications': ['PUBMED:17917096'],\n",
      "            'source_id': 'CHEBI:35341',\n",
      "            'target_id': 'MESH:D050723'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'publications': ['PUBMED:17917096'],\n",
      "            'source_id': 'CHEBI:35341',\n",
      "            'target_id': 'MESH:D008180'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'publications': ['PUBMED:17917096'],\n",
      "            'source_id': 'CHEBI:35341',\n",
      "            'target_id': 'MESH:D008775'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'}],\n",
      "            'publications': ['PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D003907',\n",
      "            'target_id': 'MESH:D013923'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'}],\n",
      "            'publications': ['PUBMED:8938892'],\n",
      "            'source_id': 'MESH:D004844',\n",
      "            'target_id': 'MESH:D012835'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'}],\n",
      "            'publications': ['PUBMED:22196580'],\n",
      "            'source_id': 'MESH:C571496',\n",
      "            'target_id': 'MESH:D009447'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:15459912'],\n",
      "            'source_id': 'NCBIGENE:14828',\n",
      "            'target_id': 'NCBIGENE:22027'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Both IL-7 and GM-CSF were also able '\n",
      "                                          'to upregulate the expression of '\n",
      "                                          'SPAN-Xb in myeloma cells , but only '\n",
      "                                          'after the promoter sequence has '\n",
      "                                          'been hypomethylated .'}],\n",
      "            'publications': ['PUBMED:16187275'],\n",
      "            'source_id': 'NCBIGENE:728695',\n",
      "            'target_id': 'NCBIGENE:3574'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'Management of disease-related '\n",
      "                                          'anemia in patients with '\n",
      "                                          'multiple_myeloma or '\n",
      "                                          'chronic_lymphocytic_leukemia : '\n",
      "                                          'epoetin treatment recommendations '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'Patients with hemoglobin 10-12 g/dl '\n",
      "                                          'should receive epoetin if they '\n",
      "                                          'suffer from significant symptoms of '\n",
      "                                          'anemia and/or have progressively '\n",
      "                                          'decreasing hemoglobin values .'}],\n",
      "            'publications': ['PUBMED:12111647', 'PUBMED:12111647'],\n",
      "            'source_id': 'NCBIGENE:2056',\n",
      "            'target_id': 'MESH:D000740'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2803933',\n",
      "                                 'value': 'A phase I clinical trial of '\n",
      "                                          'recombinant interleukin_2 following '\n",
      "                                          'high dose chemo-radiotherapy for '\n",
      "                                          'haematological_malignancy : '\n",
      "                                          'applicability to the elimination of '\n",
      "                                          'minimal residual_disease .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2803933',\n",
      "                                 'value': 'Biological response modifiers such '\n",
      "                                          'as interleukin_2 -LRB- IL2 -RRB- '\n",
      "                                          'may be most effective in the '\n",
      "                                          'setting of minimal residual_disease '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:2803933', 'PUBMED:2803933'],\n",
      "            'source_id': 'NCBIGENE:3558',\n",
      "            'target_id': 'MESH:D004194'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11843289',\n",
      "                                 'value': 'To the best of our knowledge , CD55 '\n",
      "                                          '- or CD59-deficient red cells have '\n",
      "                                          'not been detected in '\n",
      "                                          'plasma_cell_dyscrasias -LRB- PCDs '\n",
      "                                          '-RRB- .'}],\n",
      "            'publications': ['PUBMED:11843289'],\n",
      "            'source_id': 'MESH:D010265',\n",
      "            'target_id': 'NCBIGENE:1604'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'}],\n",
      "            'publications': ['PUBMED:21343556'],\n",
      "            'source_id': 'MESH:D001943',\n",
      "            'target_id': 'MESH:D009362'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/194331',\n",
      "                                 'value': 'Finally , the iatrogenic '\n",
      "                                          'manifestations of the locomotor '\n",
      "                                          'system appear mainly due to '\n",
      "                                          'hypolipemic drugs , e.g. the '\n",
      "                                          'muscle_disorders seen in a few '\n",
      "                                          'patients treated with clofibrate '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:194331'],\n",
      "            'source_id': 'MESH:D002994',\n",
      "            'target_id': 'MESH:D009135'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2081514',\n",
      "                                 'value': 'Interestingly , in sarcoidosis '\n",
      "                                          'there are calcium_oxalate crystals '\n",
      "                                          'in variously distributed '\n",
      "                                          'sarcoid_granuloma , and the '\n",
      "                                          'renal_calculi are composed of '\n",
      "                                          'calcium_oxalate .'}],\n",
      "            'publications': ['PUBMED:2081514'],\n",
      "            'source_id': 'MESH:D002129',\n",
      "            'target_id': 'MESH:D006099'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2081514',\n",
      "                                 'value': 'Interestingly , in sarcoidosis '\n",
      "                                          'there are calcium_oxalate crystals '\n",
      "                                          'in variously distributed '\n",
      "                                          'sarcoid_granuloma , and the '\n",
      "                                          'renal_calculi are composed of '\n",
      "                                          'calcium_oxalate .'}],\n",
      "            'publications': ['PUBMED:2081514'],\n",
      "            'source_id': 'MESH:D002129',\n",
      "            'target_id': 'MESH:D007669'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2081514',\n",
      "                                 'value': 'Interestingly , in sarcoidosis '\n",
      "                                          'there are calcium_oxalate crystals '\n",
      "                                          'in variously distributed '\n",
      "                                          'sarcoid_granuloma , and the '\n",
      "                                          'renal_calculi are composed of '\n",
      "                                          'calcium_oxalate .'}],\n",
      "            'publications': ['PUBMED:2081514'],\n",
      "            'source_id': 'MESH:D006099',\n",
      "            'target_id': 'MESH:D007669'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'}],\n",
      "            'publications': ['PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D007938',\n",
      "            'target_id': 'MESH:D001554'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'Other diseases of particular '\n",
      "                                          'interest in relation to gasoline '\n",
      "                                          'exposure are kidney_cancer , '\n",
      "                                          'malignant_melanoma , and '\n",
      "                                          'heart_disease .'}],\n",
      "            'publications': ['PUBMED:8020433'],\n",
      "            'source_id': 'MESH:D005742',\n",
      "            'target_id': 'MESH:D007680'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'We next studied the association of '\n",
      "                                          'MDM2 with wtp53 and/or mutant p53 '\n",
      "                                          '-LRB- mtp53 -RRB- , E2F-1 , CDK4 , '\n",
      "                                          'and p21 .'}],\n",
      "            'publications': ['PUBMED:9292533', 'PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:7157',\n",
      "            'target_id': 'NCBIGENE:4193'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:7157',\n",
      "            'target_id': 'NCBIGENE:1869'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:7157',\n",
      "            'target_id': 'NCBIGENE:644914'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:644914',\n",
      "            'target_id': 'NCBIGENE:4193'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:644914',\n",
      "            'target_id': 'NCBIGENE:1869'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'These data suggest that MDM2 may '\n",
      "                                          'enhance cell-cycle progression in '\n",
      "                                          'MM cells both by activating E2F-1 '\n",
      "                                          'and by downregulating cell-cycle '\n",
      "                                          'inhibitory proteins -LRB- wtp53 and '\n",
      "                                          'p21 -RRB- .'}],\n",
      "            'publications': ['PUBMED:9292533',\n",
      "                             'PUBMED:9292533',\n",
      "                             'PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:4193',\n",
      "            'target_id': 'NCBIGENE:1869'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:4193',\n",
      "            'target_id': 'MESH:D012175'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:4193',\n",
      "            'target_id': 'NCBIGENE:5925'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:1869',\n",
      "            'target_id': 'MESH:D012175'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:1869',\n",
      "            'target_id': 'NCBIGENE:5925'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:5925',\n",
      "            'target_id': 'MESH:D012175'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'The murine_double_minute_2 -LRB- '\n",
      "                                          'MDM2 -RRB- protein facilitates G1 '\n",
      "                                          'to S phase transition by activation '\n",
      "                                          'of E2F-1 and can enhance cell '\n",
      "                                          'survival by suppressing wild-type '\n",
      "                                          'p53 -LRB- wtp53 -RRB- function .'}],\n",
      "            'publications': ['PUBMED:9292533'],\n",
      "            'source_id': 'NCBIGENE:13555',\n",
      "            'target_id': 'NCBIGENE:17246'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'The novel , proteasome-independent '\n",
      "                                          'NF-kappaB inhibitor V1810 induces '\n",
      "                                          'apoptosis and cell cycle arrest in '\n",
      "                                          'multiple_myeloma and overcomes '\n",
      "                                          'NF-kappaB-mediated drug resistance '\n",
      "                                          '.'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Taken together , the novel , '\n",
      "                                          'proteasome-independent NF-kappaB '\n",
      "                                          'inhibitor V1810 induces apoptosis '\n",
      "                                          'and cell cycle arrest in '\n",
      "                                          'multiple_myeloma cells at a '\n",
      "                                          'concentration range that can be '\n",
      "                                          'achieved in vivo .'}],\n",
      "            'publications': ['PUBMED:20124446', 'PUBMED:20124446'],\n",
      "            'source_id': 'MESH:C553325',\n",
      "            'target_id': 'NCBIGENE:4790'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Bone_morphogenetic_protein-2 '\n",
      "                                          'induces apoptosis in human myeloma '\n",
      "                                          'cells with modulation of STAT3 .'}],\n",
      "            'publications': ['PUBMED:10979940'],\n",
      "            'source_id': 'NCBIGENE:650',\n",
      "            'target_id': 'NCBIGENE:6774'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'In studies of apoptosis-associated '\n",
      "                                          'proteins , BMP-2 was seen to '\n",
      "                                          'down-regulate the expression of '\n",
      "                                          'Bcl-x -LRB- L -RRB- ; however , '\n",
      "                                          'BMP-2 had no effects on the '\n",
      "                                          'expression of Bcl-2 , Bax , or Bad '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:10979940'],\n",
      "            'source_id': 'NCBIGENE:650',\n",
      "            'target_id': 'NCBIGENE:596'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'A Korean trial reported low TE '\n",
      "                                          'incidence in thalidomide-treated '\n",
      "                                          'myeloma patients -LRB- 39 % were '\n",
      "                                          'given aspirin prophylactically '\n",
      "                                          '-RRB- .'}],\n",
      "            'publications': ['PUBMED:22706703'],\n",
      "            'source_id': 'MESH:D013923',\n",
      "            'target_id': 'MESH:D001241'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440338',\n",
      "                                 'value': 'We studied IL-3 in 7 patients with '\n",
      "                                          'markedly delayed engraftment after '\n",
      "                                          'autologous bone marrow '\n",
      "                                          'transplantation -LRB- ABMT -RRB- '\n",
      "                                          'for hematologic_malignancies -LRB- '\n",
      "                                          'acute_myeloid_leukemia 4 , '\n",
      "                                          'chronic_myeloid_leukemia 1 , '\n",
      "                                          \"myeloma 1 , non-Hodgkin 's _ \"\n",
      "                                          'lymphoma 1 -RRB- .'}],\n",
      "            'publications': ['PUBMED:8440338'],\n",
      "            'source_id': 'MESH:D015464',\n",
      "            'target_id': 'NCBIGENE:3562'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'New signal transduction inhibitors '\n",
      "                                          ', dasatinib and nilotinib , are '\n",
      "                                          'being used in patients with '\n",
      "                                          'chronic_myelogeneous_leukaemia who '\n",
      "                                          'develop resistance to imatinib .'}],\n",
      "            'publications': ['PUBMED:18565291'],\n",
      "            'source_id': 'MESH:D015464',\n",
      "            'target_id': 'MESH:C488369'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440338',\n",
      "                                 'value': 'Interleukin-3 followed by GM-CSF '\n",
      "                                          'for delayed engraftment after '\n",
      "                                          'autologous bone marrow '\n",
      "                                          'transplantation .'}],\n",
      "            'publications': ['PUBMED:8440338'],\n",
      "            'source_id': 'NCBIGENE:3562',\n",
      "            'target_id': 'NCBIGENE:1437'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7605999',\n",
      "                                 'value': 'Furthermore , suppression of CRP '\n",
      "                                          'and worsening of '\n",
      "                                          'neutropenia/thrombocytopenia both '\n",
      "                                          'indicate that IL-6 is critically '\n",
      "                                          'involved in acute-phase responses '\n",
      "                                          'and granulopoiesis/thrombopoiesis '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:7605999'],\n",
      "            'source_id': 'NCBIGENE:3569',\n",
      "            'target_id': 'NCBIGENE:1401'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179619',\n",
      "                                 'value': 'We report two male patients who '\n",
      "                                          'presented with symmetrical , '\n",
      "                                          'painful purpura that evolved into '\n",
      "                                          'bullae and necrotic ulcers , '\n",
      "                                          'predominantly on the extremities , '\n",
      "                                          'over two months in spite of '\n",
      "                                          'conventional therapy including oral '\n",
      "                                          'steroids .'}],\n",
      "            'publications': ['PUBMED:17179619'],\n",
      "            'source_id': 'MESH:D011693',\n",
      "            'target_id': 'MESH:D014456'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179619',\n",
      "                                 'value': 'We report two male patients who '\n",
      "                                          'presented with symmetrical , '\n",
      "                                          'painful purpura that evolved into '\n",
      "                                          'bullae and necrotic ulcers , '\n",
      "                                          'predominantly on the extremities , '\n",
      "                                          'over two months in spite of '\n",
      "                                          'conventional therapy including oral '\n",
      "                                          'steroids .'}],\n",
      "            'publications': ['PUBMED:17179619'],\n",
      "            'source_id': 'MESH:D011693',\n",
      "            'target_id': 'MESH:D013256'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179619',\n",
      "                                 'value': 'We report two male patients who '\n",
      "                                          'presented with symmetrical , '\n",
      "                                          'painful purpura that evolved into '\n",
      "                                          'bullae and necrotic ulcers , '\n",
      "                                          'predominantly on the extremities , '\n",
      "                                          'over two months in spite of '\n",
      "                                          'conventional therapy including oral '\n",
      "                                          'steroids .'}],\n",
      "            'publications': ['PUBMED:17179619'],\n",
      "            'source_id': 'MESH:D014456',\n",
      "            'target_id': 'MESH:D013256'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10067092',\n",
      "                                 'value': 'Four courses of chemotherapy -LRB- '\n",
      "                                          'cyclophosphamide , doxorubicin , '\n",
      "                                          'and prednisolone -RRB- and the '\n",
      "                                          'intrathecal administration of '\n",
      "                                          'methotrexate and cytarabine at '\n",
      "                                          '3-week intervals were effective in '\n",
      "                                          'decreasing the pleural_effusions '\n",
      "                                          'and eliminating plasma cells from '\n",
      "                                          'CSF .'}],\n",
      "            'publications': ['PUBMED:10067092'],\n",
      "            'source_id': 'MESH:D003520',\n",
      "            'target_id': 'MESH:D010996'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10067092',\n",
      "                                 'value': 'A chest radiograph disclosed '\n",
      "                                          'pleural_effusion in both lungs '\n",
      "                                          'containing M-protein and numerous '\n",
      "                                          'abnormal cells .'}],\n",
      "            'publications': ['PUBMED:10067092'],\n",
      "            'source_id': 'MESH:D010996',\n",
      "            'target_id': 'NCBIGENE:9172'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'}],\n",
      "            'publications': ['PUBMED:4079014'],\n",
      "            'source_id': 'MESH:D006402',\n",
      "            'target_id': 'MESH:D001398'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'},\n",
      "                                {'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'These results indicate that AZT is '\n",
      "                                          'an effective and safe antibiotic '\n",
      "                                          'for the treatment of infections '\n",
      "                                          'accompanying hematologic_disorders '\n",
      "                                          '.'}],\n",
      "            'publications': ['PUBMED:4079014', 'PUBMED:4079014'],\n",
      "            'source_id': 'MESH:D006402',\n",
      "            'target_id': 'MESH:D015215'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'}],\n",
      "            'publications': ['PUBMED:4079014'],\n",
      "            'source_id': 'MESH:D001398',\n",
      "            'target_id': 'MESH:D015215'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'publications': ['PUBMED:17917096'],\n",
      "            'source_id': 'MESH:D008180',\n",
      "            'target_id': 'MESH:D050723'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'publications': ['PUBMED:17917096'],\n",
      "            'source_id': 'MESH:D008180',\n",
      "            'target_id': 'MESH:D008775'},\n",
      "           {'edge_attributes': [{'type': 'sentence',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'publications': ['PUBMED:17917096'],\n",
      "            'source_id': 'MESH:D050723',\n",
      "            'target_id': 'MESH:D008775'}],\n",
      " 'nodes': [{'id': 'MESH:D018376',\n",
      "            'name': 'laboratory abnormalities',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:2152', 'name': 'TF', 'type': ['Gene']},\n",
      "           {'id': 'MESH:C088658',\n",
      "            'name': 'zoledronic acid',\n",
      "            'type': ['Chemical']},\n",
      "           {'id': 'MESH:D009369', 'name': 'tumor', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D007239', 'name': 'infection', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D010400', 'name': 'penicillin G', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:C020766', 'name': 'MCNU', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D019337',\n",
      "            'name': 'hematologic malignancies',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'MESH:D009101', 'name': 'myeloma', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D013792', 'name': 'thalidomide', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D007674', 'name': 'nephropathy', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D058186', 'name': 'AKI', 'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:1636', 'name': 'ACE', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D003404', 'name': 'creatinine', 'type': ['Chemical']},\n",
      "           {'id': 'CHEBI:35341', 'name': 'steroid', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D064420', 'name': 'toxicity', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D003907',\n",
      "            'name': 'dexamethasone',\n",
      "            'type': ['Chemical']},\n",
      "           {'id': 'MESH:D012514', 'name': 'KS', 'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:2247', 'name': 'bFGF', 'type': ['Gene']},\n",
      "           {'id': 'MESH:C400082', 'name': 'bortezomib', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D004844', 'name': 'epistaxis', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D012835',\n",
      "            'name': 'silver nitrate',\n",
      "            'type': ['Chemical']},\n",
      "           {'id': 'MESH:D002292', 'name': 'RCC', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D004893', 'name': 'ENL', 'type': ['Disease']},\n",
      "           {'id': 'MESH:C571496', 'name': 'TIR-203', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D009447', 'name': 'neuroblastoma', 'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:5290', 'name': 'PIK3CA', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:14828', 'name': 'GRP78', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:22027', 'name': 'gp96', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:728695', 'name': 'SPAN-Xb', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D001374', 'name': 'azacitidine', 'type': ['Chemical']},\n",
      "           {'id': 'NCBIGENE:3574', 'name': 'IL-7', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:9947', 'name': 'MAGE-C1', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:2056', 'name': 'erythropoietin', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D000740', 'name': 'anemia', 'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:3558', 'name': 'IL-2', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D004194',\n",
      "            'name': 'coeliac disease',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'MESH:D010265',\n",
      "            'name': 'monoclonal gammopathy',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:1604', 'name': 'CD55', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D001943', 'name': 'breast cancer', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D009362', 'name': 'metastasis', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D002994', 'name': 'clofibrate', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D009135', 'name': 'myopathy', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D002129',\n",
      "            'name': 'calcium oxalate',\n",
      "            'type': ['Chemical']},\n",
      "           {'id': 'MESH:D006099', 'name': 'granuloma', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D007669', 'name': 'kidney stones', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D008715', 'name': 'methionine', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D007938', 'name': 'leukemia', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D001554', 'name': 'benzene', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D005742', 'name': 'gasoline', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D007680', 'name': 'renal cancer', 'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:7157', 'name': 'p53', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:644914', 'name': 'p21', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:4193', 'name': 'MDM2', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:1869', 'name': 'E2F1', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:5925', 'name': 'pRb', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D012175',\n",
      "            'name': 'retinoblastoma',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:13555', 'name': 'E2F1', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:17246', 'name': 'MDM2', 'type': ['Gene']},\n",
      "           {'id': 'MESH:C553325', 'name': 'V1810', 'type': ['Chemical']},\n",
      "           {'id': 'NCBIGENE:4790', 'name': 'NF-kappaB', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:650', 'name': 'BMP-2', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:6774', 'name': 'STAT3', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:596', 'name': 'Bcl-2', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D013927', 'name': 'thrombosis', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D013923',\n",
      "            'name': 'thromboembolism',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'MESH:D001241', 'name': 'aspirin', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D054556', 'name': 'VTE', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D015464', 'name': 'CML', 'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:3562', 'name': 'IL-3', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:1437', 'name': 'GM-CSF', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:3569', 'name': 'IL-6', 'type': ['Gene']},\n",
      "           {'id': 'NCBIGENE:1401', 'name': 'CRP', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D011693', 'name': 'purpura', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D014456', 'name': 'ulcer', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D013256', 'name': 'steroids', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:C488369', 'name': 'dasatinib', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:C467567', 'name': 'lenalidomide', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D008558', 'name': 'melphalan', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D003520',\n",
      "            'name': 'cyclophosphamide',\n",
      "            'type': ['Chemical']},\n",
      "           {'id': 'MESH:D010996',\n",
      "            'name': 'pleural effusion',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'NCBIGENE:9172', 'name': 'M-protein', 'type': ['Gene']},\n",
      "           {'id': 'MESH:D006402',\n",
      "            'name': 'hematologic toxicity',\n",
      "            'type': ['Disease']},\n",
      "           {'id': 'MESH:D001398', 'name': 'aztreonam', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D015215', 'name': 'zidovudine', 'type': ['Chemical']},\n",
      "           {'id': 'MESH:D008180', 'name': 'SLE', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D050723', 'name': 'fracture', 'type': ['Disease']},\n",
      "           {'id': 'MESH:D008775',\n",
      "            'name': 'methylprednisolone',\n",
      "            'type': ['Chemical']}]}\n"
     ]
    }
   ],
   "source": [
    "from pprint import pprint\n",
    "\n",
    "pprint(result_graph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
